PWZ-029

PWZ-029

Identifiers
IUPAC name 8-chloro-3-(methoxymethyl)-5-methyl-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one
PubChem (CID)	9971547
ChEMBL	CHEMBL45346
Chemical and physical data
Formula	C14H14ClN3O2
Molar mass	291.732 g/mol
3D model (Jmol)	Interactive image
SMILES ClC1=CC=C2C(C(N(CC3=C(COC)N=CN32)C)=O)=C1
(what is this?)  (verify)

PWZ-029 is a benzodiazepine derivative drug with nootropic effects developed by WiSys,^[1] It acts as a subtype-selective, mixed agonist-inverse agonist at the benzodiazepine binding site on the GABA_A receptor, acting as a partial inverse agonist at the α₅ subtype and a weak partial agonist at the α₃ subtype. This gives it a mixed pharmacological profile, producing at low doses memory-enhancing effects but with no convulsant or anxiogenic effects or muscle weakness, although at higher doses it produces some sedative effects.^[2]

See also

• α₅IA
• Basmisanil
• L-655,708
• Ro4938581
• TB-21007

References

1. US Patent application US2006/258643 A1
2. Savić MM, Clayton T, Furtmüller R, Gavrilović I, Samardzić J, Savić S, Huck S, Sieghart W, Cook JM. PWZ-029, a compound with moderate inverse agonist functional selectivity at GABA(A) receptors containing alpha5 subunits, improves passive, but not active, avoidance learning in rats. Brain Research. 2008 May 7;1208:150-9. doi:10.1016/j.brainres.2008.02.020 PMID 18394590